Microphyt Raises €28.5 Million to Develop Its Portfolio of Microalgae-based Natural Solutions for Nutrition and Well-being
Microphyt, a leading company in microalgae-based natural solutions for nutrition and well-being, announced a fundraising of €28.5 million (US$32 million). This investment was co-led by Sofinnova Partners and BPI France via the SPI fund ("Sociétés de projets industriels") managed as part of the “Programme d'investissements d'avenir”, together with IXO-Private Equity and Sofilaro. The existing investors, Supernova Invest, Demeter Partners and Irdi Soridec, renew their confidence in the company by participating in this new round. The funds will be used to accelerate the development of the product portfolio, expand sales network globally, as well as to increase production capacity of Microphyt's industrial platform.
In nutrition and wellbeing, consumer demand for natural, effective, safe and sustainably produced solutions is booming. The world market for ingredients for these markets, represents more than US$ 70 billion with a share of natural ingredients (US$ 5 billion) that shows the strongest growth (8% per year). Among the natural ingredients, microalgae best meet consumer expectations thanks to their natural diversity, offering richness of molecules that can be produced in a close-controlled and sustainable way.
Since 2009, Microphyt has developed a proprietary production technology that makes it possible to access this diversity while guaranteeing a high level of control and standardization. This patented process, developed in-house, solves the usual drawbacks of microalgae production. It is based on 5,000-litre tubular photobioreactors, which offer both high differentiation potential (access to a new diversity of species) and the ability to supply natural active ingredients in an industrial and standardized way. This technology, operated within an industrial production platform, has already made it possible to establish several commercial partnerships with key players in the sector.
Microphyt has also launched the development of new products that contribute to improving the well-being of the elderly, preventing certain metabolic disorders, facilitating an active lifestyle and protecting the skin from various stresses. A portfolio of 10 nutritional active ingredients and 20 cosmetic active and functional ingredients is being developed. To achieve this, Microphyt will strengthen its team and will significantly increase its ingredient production capacity over the next 18 months.
"This new round is a major milestone in our development and we are pleased that recognized investors in the sector such as Sofinnova Partners and Bpifrance are joining us alongside our existing investors to accelerate our development and internationalization," said Vincent Usache, CEO of Microphyt. "For several years now, Microphyt was actively committed to unlocking the full potential of microalgae amazing diversity through our unique technology platform. With this funding, we will speed up the development and supply of novel natural products that solve the key challenges of Nutrition & Well-being”.
"Microphyt is exactly the type of company that Sofinnova Partners is looking for as a pioneering investor in industrial biotechnology: thanks to its proprietary technology platform and unique production capacity that allows access to the exceptional biodiversity of microalgae, the company is in an ideal position to become one of the world leaders in natural ingredients dedicated to nutrition and well-being," says Denis Lucquin, Managing Partner of Sofinnova Partners.
"Microphyt's innovations are also based on an innovative industrial project," explains Jean Philippe Richard, Investment Director of the SPI Fund of Bpifrance. "We share this ambition to develop a leading industrial production site in France and to create a European leader with a global vocation. The site will offer multi-product production with high added value while implementing environmentally friendly processes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190711005023/en/
Contact information
Anne REIN
S&I for Microphyt
+33 6 03 35 92 05
anne.rein@strategiesimage.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO ® (lanadelumab) in Reducing Hereditary Angioedema Attacks6.6.2020 09:05:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses suggest that TAKHZYRO® (lanadelumab) is well-tolerated and can prevent hereditary angioedema (HAE) attacks over an extended treatment period, with sustained and consistent reduction in monthly attack rate across a range of different patient subgroups. The data are being presented at the 2020 European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress. The original Phase 3 HELP Study was conducted in 125 patients aged 12 years and older over 26 weeks, making it the largest randomised, controlled prevention study in HAE, with the longest active treatment duration, to date.1 The HELP Study OLE was designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO for up to 2.5 years and was completed in Novemb
FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump5.6.2020 13:00:00 CEST | Press release
Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP™ heart pump. Impella ECP, which stands for expandable cardiac power, will be studied in high-risk percutaneous coronary intervention (PCI) patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005049/en/ FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump Impella ECP is the world’s smallest heart pump. It achieves peak flows greater than 3.5 L/min and is delivered though a slender-profile sheath. It is un-sheathed in the descending aorta and expands to approximately 18 Fr. Using a specially designed pigtail, it crosses the aortic valve without a wire, and pumps from inside the ventricle. When the procedure is complete, the pump is
Next generation of DataOps, provided by Datalytyx, now available through Snowflake Partner Connect Program!5.6.2020 11:10:00 CEST | Press release
Datalytyx today announced an expanded partnership with Snowflake, the Cloud Data Platform, that enables the next generation Datalytyx DataOps for Snowflake platform to be deployed for a 2 week trial on Snowflake. Customers can orchestrate the ingestion of data from many on-premise and cloud platforms via 3rd party data tools, model data easily, automatically test those models as part of their pipelines, launch AI/ML models and enable the consumption of data to deliver immediate stakeholder value. As a great example, in the midst of the Coronavirus pandemic, BOC, the UK market-leading gas supply company for delivery of healthcare oxygen, has faced unprecedented demand, from equipping Nightingale hospitals to delivering O2 cylinders in homes. Datalytyx have deployed their DataOps for Snowflake platform to help BOC manage their cylinder stock and logistics data, for all types of gases, to increase production efficiency and provide best-in-class customer service. “Datalytyx said they could
Pegasus Development AG: Green Light for Multiple Production Sites Worldwide5.6.2020 09:27:00 CEST | Press release
Announcement: Expansion of the Pegastril-Nuevo production facility Under the leadership of board member Roberto Spano, the management of Pegasus Development AG has decided to further expand Pegastril-Nuevo production facilities. New production facilities will be set up at several locations across the world and the site in Turkey is being expanded. These investments will also create new jobs. The takeover and expansion of the following production facilities are planned in all 20 countries of Latin America, as well as France, Spain, Portugal, Greece, Cyprus, Nigeria, Ethiopia, Uganda, Tanzania, Mozambique, Angola, Mauritius, Guinea-Bissau, Cape Verde, São Tome, and Mongolia. The demand for disinfectants has skyrocketed as a result of the coronavirus. Especially high revenues are expected from products which are based on vegetable surfactants and are alcohol-free, such as Nuevo. This was the decisive factor in the management's decision to further expand the quantity and range of Nuevo pro
In COVID-19, Pudu Robotics Provides Non-contact Delivery Service in Hundreds of Hospitals Worldwide5.6.2020 09:00:00 CEST | Press release
During COVID-19, hundreds of Pudu Robotics’ robot Pudubot is offering delivery service in hospitals worldwide. This non-contact delivery service by Pudubot helps avoid the spread of virus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005095/en/ (Photo: Business Wire) After the outbreak of COVID-19, the pandemic with the characteristic of human-to-human transmission, a large number of hospitals and restaurants are seeking help from Pudu Robotics out of an urgent need for non-contact delivery. Pudu Robotics responded positively by devoting robots to several hospitals in Seoul, South Korea, Beijing, China, Wuhan, China and so on. Because Pudu Robotics’ robots are fully automatic, they can achieve the delivery process all by themselves, which reduces contact between people and effectively prevents the spread of the virus. Pudubot is equipped with multi-sensor and positioning and navigation technology. With large-capacity
IDEMIA and BBVA Partner to Launch Spain’s First Payment Card Made of Recycled PVC5.6.2020 09:00:00 CEST | Press release
IDEMIA, the global leader in Augmented Identity, is supplying the very first cards made out of recycled plastics in Spain to BBVA. The bank will first distribute the cards to their Spanish customers with a BBVA Youth Account in June 2020. This new payment card is a strong commitment from BBVA to contributing to the United Nations Sustainable Development Goals for the fight against climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005037/en/ (Graphic: Business Wire) Each year, approximately 6 billion plastic payment cards are produced according to the 2018 Nilson Report1. In the context of the United Nations Sustainable Development Goals and the Paris Agreement, IDEMIA’s cutting-edge technology has been selected by BBVA, one of the largest banks in Spain, to migrate part of its existing first-use PVC cards to innovative recycled PVC cards. By the end of the year BBVA will enable more than half a million Spa